Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular

Yikun Jiang1, Shibo Wei2, Jin-Mo Koo3

  • 1Department of Orthopedics, The Second Hospital of Jilin University, Changchun 130041, China.

Cancers
|August 26, 2023
PubMed

Insights

Protein arginine methyltransferases (PRMTs) show significant associations with prognosis in hepatocellular carcinoma (HCC) patients. PRMT1 plays a pivotal role in HCC progression, offering potential as a novel therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • Limited effective treatments exist for advanced HCC, necessitating new therapeutic targets.
  • Protein arginine methyltransferases (PRMTs) are implicated in various cancers, but their role in HCC is unclear.

Purpose of the Study:

  • To evaluate the expression patterns and clinical significance of PRMTs in HCC.
  • To identify PRMTs as potential prognostic biomarkers for HCC.
  • To investigate the specific role of PRMT1 in HCC progression.

Main Methods:

  • Analysis of transcriptional expression of PRMTs in HCC patient cohorts using public datasets.
  • Utilized single-cell RNA sequencing (scRNA) analysis.
  • Correlated PRMT expression with clinical characteristics and patient prognosis.

Main Results:

  • Significant associations were found between PRMT expression and prognosis in HCC patients.
  • PRMTs demonstrate potential as prognostic biomarkers for HCC.
  • PRMT1 was identified as a key player in HCC progression, especially in T-cell exhaustion (Tex) contexts.

Conclusions:

  • PRMTs are promising prognostic biomarkers for hepatocellular carcinoma.
  • PRMT1 plays a critical role in HCC progression and represents a potential therapeutic target.
  • Findings may inform novel therapeutic strategies for advanced HCC patients.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K